Bridgene Biosciences Announces $38.5 Million Series B Financing To Further Develop Its Next Generation Chemoproteomics Platform And First-In-Class Oncology Drugs
PRIVATEJul 27, 2022
Amount Raised
$38.5 Million
Round Type
Series B
San JoseBiotechnologyTherapeutics
Description
BridGene Biosciences, Inc., a biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule drugs for high-value, traditionally undruggable targets, today announced the completion of a $38.5 million Series B financing by Lapam Capital, Junson Capital and Dyee Capital.
Who to call at BridGene Biosciences, and when
A new round usually means BridGene Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day BridGene Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at BridGene Biosciences, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
BridGene Biosciences
Location
San Jose, California, United States
About
BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridGene Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San JoseBiotechnologyTherapeutics